Skip to main content
. 2020 Dec 15;10:21976. doi: 10.1038/s41598-020-78892-0

Table 1.

Characteristics of patients with advanced nasopharyngeal carcinoma according to EBV status.

Variables Total patients
N = 146 (%)
EBV infection
Positive
N = 87 (%)
Negative
N = 59 (%)
P value
Age at IV stage, yrs
Mean SD (median) 50.07 ± 11.25 50.11 ± 11.02 50.00 ± 11.77 0.952
Range 21–78 26–75 21–78
 < 50 73 (50.0) 44 (50.6) 29 (49.2) 0.866
 ≥ 50 73 (50.0) 43 (49.4) 30 (50.8)
Sex 0.060
Male 113 (77.4) 72 (82.8) 41 (69.5)
Female 33 (22.6) 15 (17.2) 18 (30.5)
Smoker 0.521
Yes 74 (50.7) 46 (52.9) 28 (47.5)
No 72 (49.3) 41 (47.1) 31 (52.5)
HBsAg 0.403
Positive 21(15.3) 14(17.5) 7(12.3)
Negative 116(84.7) 66(82.5) 50(87.7)
T-stage 0.871
Tx-3 105 (71.9) 63 (72.4) 42 (71.2)
T4 41 (28.1) 24 (27.6) 17 (28.8)
N-stage 0.370
N0-2 102 (69.9) 58 (19.0) 44 (74.6)
N3 44 (30.1) 29 (81.0) 15 (25.4)
M-stage 0.147
M0 40 (27.4) 20(23.0) 20 (33.9)
M1 106 (72.6) 67 (77.0) 39 (66.1)
Clinical stage 0.349
IVa 18 (12.3) 9 (10.3) 9 (15.3)
IVb 22 (15.1) 11 (12.7) 11 (18.6)
IVc 106 (72.6) 67 (77.0) 39 (66.1
Lung metastases 0.789
Yes 32 (21.9) 19 (21.8) 13 (22.0)
No 114 (78.1) 68 (78.2) 46 (78.0)
Liver metastases 0.040
Yes 38 (26.0) 28 (32.2) 10 (16.9)
No 108 (74.0) 59 (67.8) 49 (83.1)
Bone metastases 0.121
Yes 53 (36.3) 36 (41.4) 17 (28.8)
No 93 (63.7) 51 (58.6) 42 (71.2)
Prior radiotherapy 0.278
Yes 59 (40.4) 32 (36.8) 27 (45.8)
No 87 (59.6) 55 (63.2) 32 (54.2)
Prior chemotherapy 0.220
Yes 58 (39.7) 31 (35.6) 27 (45.8)
No 88 (60.3) 56 (64.4) 32 (54.2)
HBsAg positive 0.345
Yes 21 (14.4) 14 (16.1) 7 (11.9)
No 116 (79.4) 66 (75.9) 50 (84.7)
Unknown 9 (6.2) 7 (8.0) 2 (3.4)